izalontamab brengitecan (BL-B01D1) - BMS, Systimmune
Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology
Phase II Study of Izalontamab Brengitecan (iza-bren) Combined with Toripalimab in Patients with Recurrent or Metastatic (R/M) Nasopharyngeal Cancer (NPC) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #243RO; Pres time: Dec 6, 2026; 11:10 AM - 11:15 AM; Location: Hall 407; No abstract available 
Clinical • Metastases • P2 data • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor
https://cslide.ctimeetingtech.com/asia2026/attendee/confcal/print/presentation/1629
 
Yuanyuan Zhao; Li Zhang; Shao Dong Hong; Gang Chen; Feng Lei; Yaqian Han; Li Xiang; Bihui Li; Kunyu Yang; Leiya Du; Jianli Huang; Peng Zhang; Jinsheng Hong; Bin Deng; Tiansheng Gao; Na Li; Sa Xiao; Hai Zhu; Yi Zhu
 
Oct 1, 2026
 
Prev Next